217 related articles for article (PubMed ID: 36090992)
21. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
Choksi TT; Zhang H; Chen T; Malhotra N
Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
[TBL] [Abstract][Full Text] [Related]
22. Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.
Yin J; Wang C; Song X; Li X; Miao M
Am J Hypertens; 2022 May; 35(5):462-469. PubMed ID: 35512430
[TBL] [Abstract][Full Text] [Related]
23. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
24. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
[TBL] [Abstract][Full Text] [Related]
25. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
26. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
[TBL] [Abstract][Full Text] [Related]
27. Associastion of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19.
Vahedian-Azimi A; Rahimibashar F; Najafi A; Kidde J; Shahriary A; Shojaei S; Pourhoseingholi MA; Jamialahmadi T; Sahebkar A
Adv Exp Med Biol; 2021; 1327():205-214. PubMed ID: 34279841
[TBL] [Abstract][Full Text] [Related]
28. Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study.
Landolfo M; Maino A; Di Salvo E; Fiorini G; Peterlana D; Borghi C
Intern Emerg Med; 2022 Aug; 17(5):1335-1341. PubMed ID: 35064437
[TBL] [Abstract][Full Text] [Related]
29. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.
Chen C; Wang F; Chen P; Jiang J; Cui G; Zhou N; Moroni F; Moslehi JJ; Ammirati E; Wang DW
J Am Heart Assoc; 2020 Nov; 9(21):e017736. PubMed ID: 32807002
[TBL] [Abstract][Full Text] [Related]
30. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
31. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
[TBL] [Abstract][Full Text] [Related]
32. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
33. Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19.
Rocheleau GLY; Lee T; Mohammed Y; Goodlett D; Burns K; Cheng MP; Tran K; Sweet D; Marshall J; Slutsky AS; Murthy S; Singer J; Patrick DM; Du B; Peng Z; Lee TC; Boyd JH; Walley KR; Lamontagne F; Fowler R; Winston BW; Haljan G; Vinh DC; McGeer A; Maslove D; Patrigeon SP; Mann P; Donohoe K; Hernandez G; Russell JA;
Crit Care Med; 2022 Sep; 50(9):1306-1317. PubMed ID: 35607951
[TBL] [Abstract][Full Text] [Related]
34. Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: Meta-analysis.
Yokoyama Y; Aikawa T; Takagi H; Briasoulis A; Kuno T
J Med Virol; 2021 Apr; 93(4):2084-2089. PubMed ID: 33038021
[TBL] [Abstract][Full Text] [Related]
35. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.
Sanam K; Bhatia V; Bajaj NS; Gaba S; Morgan CJ; Fonarow GC; Butler J; Deedwania P; Prabhu SD; Wu WC; White M; Love TE; Aronow WS; Fletcher RD; Allman RM; Ahmed A
Am J Med; 2016 Oct; 129(10):1067-73. PubMed ID: 27262781
[TBL] [Abstract][Full Text] [Related]
36. Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection.
Chaudhri I; Koraishy FM; Bolotova O; Yoo J; Marcos LA; Taub E; Sahib H; Bloom M; Ahmad S; Skopicki H; Mallipattu SK
Kidney360; 2020 Aug; 1(8):801-809. PubMed ID: 33345195
[TBL] [Abstract][Full Text] [Related]
37. The Association between Chronic Use of Renin-Angiotensin-Aldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with Hypertension.
Cetinkal G; Kocas BB; Ser OS; Kilci H; Yildiz SS; Ozcan SN; Verdi Y; Altinay M; Kilickesmez K
Sisli Etfal Hastan Tip Bul; 2020; 54(4):399-404. PubMed ID: 33364877
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study.
Kim JH; Baek YH; Lee H; Choe YJ; Shin HJ; Shin JY
Epidemiol Health; 2021; 43():e2021004. PubMed ID: 33445824
[TBL] [Abstract][Full Text] [Related]
40. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
